FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vuoimigton,	D.O.	_00.0

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Utter Christine Marie (Last) (First) (Middle) C/O PTC THERAPEUTICS, INC.					Issuer Name and Ticker or Trading Symbol PTC THERAPEUTICS, INC. [PTCT] 3. Date of Earliest Transaction (Month/Day/Year) 03/29/2023								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
													X Officer below)	Officer (give title below) SVP, FINANG		Other (below)	specify	
	CTHERAP. RPORATE (4. 1	f Amer	ndmer	nt, Date	of Origin	nal Fi	led (Month/D	ay/Year)		ndividual or	Joint/Group	Filing	(Check Ap	pplicable
(Street)			-									e) <mark>X</mark> Form f	Form filed by One Reporting Person					
SOUTH	UTH NI 07080											Form f Persor	filed by Mor	e thar	One Repo	orting		
PLAINFIELD 173 07080			R	Rule 10b5-1(c) Transaction Indication														
(City)	(S	tate)	(Zip)		X	Chec	k this y the	box to ir affirmati	ndicate the	at a tra	ansaction was ditions of Rule	made purs 10b5-1(c).	uant to a con See Instructi	tract, instruct on 10.	ion or written	ı plan t	that is intend	ed to
		Tab	le I - I	Non-Deri	vativ	e Sec	urit	ies A	cquire	d, D	isposed o	of, or B	eneficial	y Owned	t			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/			Execution Date,		Transaction Disposed Of Code (Instr.		s Acquired (A) or f (D) (Instr. 3, 4 and 5)		Securit Benefic Owned	5. Amount of Securities Beneficially Owned Following		wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership					
									Code	v	Amount	(A) or (D)	Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common	Stock			03/29/2023					M ⁽¹⁾		4,688	A	\$40.45	42	12,747		D	
Common	Stock			03/29/2023				S ⁽¹⁾		3,247	D	\$47.7980	(2) 39,500		00 D			
Common Stock		03/29/2	29/2023		3		S ⁽¹⁾		1,441	D	\$47.7752	(2) 38	38,059		D			
		7	Table								posed of , converti			Owned				
1. Title of	2.	3. Transaction	3A. De	emed	4.		5. N	umber	6. Date	Exerc	isable and	7. Title a	nd Amount	8. Price of	9. Number	of	10.	11. Nature
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security		Execution Date, if any (Month/Day/Year)		Transa Code (8)				Expiration Da (Month/Day/Y			of Secur Underlyi Derivativ (Instr. 3 a	ng e Security	Derivative Security (Instr. 5)	derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$40.45	03/29/2023			M ⁽¹⁾			4,688	(3)		09/23/2024	Common Stock	4,688	\$40.45	0		D	
Stock Option (Right to Buy)	\$51								(3)		01/02/2025	Common Stock	17,800		17,800		D	
Stock Option (Right to Buy)	\$33.02								(3)		01/21/2029	Common Stock	4,321		4,321		D	
Stock Option (Right to Buy)	\$33.02								(3)		01/21/2029	Common Stock	371		371		D	
Stock Option (Right to Buy)	\$51.16								(4)		01/28/2030	Common Stock	23,800		23,800)	D	
Stock Option (Right to Buy)	\$66.49								(5)		01/05/2031	Common Stock	50,750		50,750		D	
Stock Option (Right to Buy)	\$38.1								(6)		01/06/2032	Common Stock	43,500		43,500		D	
Stock Option (Right to	\$39.42								(7)		01/04/2033	Common Stock	32,500		32,500		D	

Explanation of Responses:

- $1.\ This\ transaction\ was\ effected\ pursuant\ to\ a\ written\ Rule\ 10b5-1\ plan\ adopted\ by\ the\ reporting\ person\ on\ February\ 24,2023.$
- 2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$47.50 to \$48.285 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. Currently exercisable.

- 4. This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
- 5. Represents an option award of 33,250 options and an option award of 17,500 options. These option awards were each granted on January 6, 2021, and each vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.
- 6. This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.
- 7. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

/s/ Avraham S. Adler,
Attorney-in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.